News Hub | News Direct


Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Cloud DX 2024 momentum continues with 2 new contracts with Ontario Community Paramedic Services

Cloud DX

Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to share exciting news about the company's continued growth and expansion in the healthcare sector. Cloud DX has signed two new 24-month Master Deployment Agreements with the Beausoleil First Nation Paramedic Service and another Ontario County Paramedic Service. These agreements highlight Cloud DX's commitment to providing innovative Connected Health RPM products and services to support community paramedics in monitoring seniors where they live, thereby extending their ability to stay at home and reducing pressure on nursing home waiting lists. These recent agreements mark the 9th and 10th Ontario Paramedic Services to contract with Cloud DX, underscoring the company's growing presence and impact in the region. Kaul emphasized that 2024 has been a year of significant growth for Cloud DX, with the company securing 10 new contracts and renewing 14 existing contracts, totaling $4.75 million CAD in value so far. Cloud DX's Connected Health RPM solutions empower paramedics and healthcare providers to deliver remote patient monitoring and care management services, enhancing patient outcomes and reducing healthcare costs. By leveraging innovative technology and partnerships with paramedic services, Cloud DX is driving positive change in the healthcare landscape, improving access to care and supporting seniors' ability to age in place comfortably. The company's continued success and expansion underscore its commitment to advancing healthcare delivery through digital innovation and patient-centered care solutions. Contact Details Proactive North America +1 604-688-8158

April 10, 2024 02:57 PM Eastern Daylight Time

Article thumbnail News Release

LightPath Technologies announces commercialization for BlackDiamond-NRL Based New Infrared Glass

LightPath Technologies Inc

LightPath Technologies CEO Sam Rubin joined Steve Darling from Proactive to announce the commercial release of the company's newest BlackDiamond-NRL infrared glass, BDNL-4. This material represents a significant advancement and is a crucial component of the chalcogenide glass series licensed from the US Naval Research Laboratories (NRL), serving as a substitute for Germanium. Rubin explained to Proactive that BDNL-4 possesses a negative thermo-optic coefficient, a critical characteristic for creating athermalized systems. This feature enables the design of devices that remain unaffected by temperature changes. Furthermore, BDNL-4 is a genuine multi-spectral material suitable for use across short-wave infrared (SWIR), mid-wave infrared (MWIR), and long-wave infrared (LWIR) imaging bands. LightPath offers antireflective and protective DLC coatings for all its Chalcogenide materials, including BDNL-4. After years of development at NRL, BDNL-4 is exclusively licensed to LightPath. The company anticipates that BDNL-4 could become a pivotal material for thermal cameras used in drones and other systems requiring operation across a wide range of temperatures. This launch is particularly significant in light of export restrictions imposed on Germanium and Gallium by China, underscoring the strategic importance of BDNL-4 as a viable alternative. Contact Details Proactive North America Proactive North America +1 604-688-8158

April 10, 2024 09:32 AM Pacific Daylight Time

Article thumbnail News Release

KME Insurance Brokerage Partners with ICON


ICON, a joint venture between AIMCOR Group, LLC (“AIMCOR”) and AmeriLife Group, LLC (“AmeriLife”), announced today that it has entered into a partnership with KME Insurance Brokerage, a leading, national brokerage firm that specializes in corporate and individual disability and life insurance. Per the agreement, terms of the deal were not disclosed. “I’m excited to partner with Steve Heney and his team and look forward to a bright future for KME as part of ICON,” said Marc Verbos, president of ICON. “This partnership further highlights our vision and dedication to create a platform that combines expertise, resources and innovation to offer value to our affiliates. KME's knowledge of the disability market strengthens our overall capabilities and enables our affiliates to broaden the range of services they offer their agents, allowing them to have a greater impact on the lives of their clients." Founded in 2007 and headquartered in Chicago, KME was built to serve and grow the businesses of employee benefit firms and independent producers to assist their clients with disability and life insurance protection. With more than 100 years of combined industry experience, KME’s in-house experts provide comprehensive support, including point-of-sale assistance, benefits implementation, case manager coordination, underwriting assistance and post-issue client administration. The team’s hands-on approach and deep product knowledge have helped the firm earn a strong reputation for excellence in service, which has been a major engine for its growth and persistency. “The KME Team is excited to partner with ICON,” said Heney, principal of KME. “This collaboration will allow us to expand our footprint and further educate producers on the importance of income protection and life insurance. This partnership will not only enhance our services, but also provide our producers with even more valuable resources and support.” As part of ICON, KME will gain access to new life insurance and annuity products, among other leading resources, and become a part of a rapidly expanding AmeriLife Wealth Group, which aims to deliver best-in-class services to the modern agent and financial professional to ensure their clients – no matter their stage of life – never outgrow them. “Continuing to add to ICON’s strong, diverse roster of partners is a crucial piece of AmeriLife Wealth Group’s long-term strategy to transform wealth distribution,” added Mike Vietri, Chief Distribution Officer of AmeriLife Wealth Group. “I’m thrilled to welcome Steve to our growing platform and look forward to watching his business grow and thrive under Marc’s leadership.” ### About KME Insurance Brokerage Founded in 2007, KME Insurance Brokerage specializes in both disability and life insurance to assist benefit consultants and independent producers with their clients’ needs. KME’s experts’ combined 100-plus years of experience is a testament to its knowledge and relationships within the industry, providing unparalleled results for its affiliated brokers. For more information, visit About ICON ICON (“AIMCOR Consolidated LLC”) is a joint venture between AIMCOR Group, LLC and AmeriLife Group, LLC. By combining the power of a premier national marketing organization (“NMO”) with capital resources, ICON offers brokerage distributors access to innovative technology, a multi-product platform and a robust suite of centralized shared services to better scale their business, protect their legacy, and enhance their service offerings. As part of ICON, affiliates not only benefit from access to resources and distribution, they join a community that allows them to maximize their entrepreneurial spirit and drive innovation, be at the forefront of transformation, take a long-term view, and most importantly make a greater impact on the lives of their team, their agency, and their communities. For more information, visit, and follow ICON on LinkedIn. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and financial professionals and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit, and follow AmeriLife on Facebook and LinkedIn. Contact Details AmeriLife | Media Jeff Maldonado ICON | Media Mike English Partnership Inquiries Patrick Nichols Company Website

April 10, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial


By Faith Ashmore, Benzinga Unfortunately, an increase in early-onset pancreatic cancer has garnered significant media attention lately. From 2010-2019, gastrointestinal cancer rates jumped almost 15% for people under 50, alarming doctors around the globe. With only a 12% five-year survival rate, pancreatic cancer is anticipated to become the second leading cause of cancer-related deaths in the U.S. by 2030. It is projected that 64,440 Americans will receive a pancreatic cancer diagnosis in 2024. In 2022, the global market for pancreatic cancer was valued at $2.22 billion, and it is projected to reach approximately $7.91 billion by 2032. This highlights a crucial need for more therapeutic options for pancreatic cancer. Oncotelic Therapeutics (OTCQB: OTLC), a therapeutics company with a focus on cancer and viral infection treatments, is attempting to provide more hope for Americans who are facing a pancreatic cancer diagnosis. The company’s lead immuno-oncology drug candidate is OT-101. Oncotelic Therapeutics says it is showing promise in the treatment of deadly cancers like pancreatic cancer. It is a first-in-class anti-TGF-β RNA therapeutic that inhibits a protein called Transforming Growth Factor Beta (TGF-β). TGF-β is known to suppress the immune system, help cancer cells evade the immune system and increase the growth and spread of cancer cells. Clinical Trial For OT-101 Phase 2 studies of OT-101 have shown promising results in treating pancreatic cancer, melanoma and glioblastoma, with strong efficacy and safety outcomes among treated patients. Pancreatic cancer is one of the most highly aggressive types of cancer that can be difficult to treat and has a high unmet need. Oncotelic Therapeutics is now seeking participants for its upcoming STOP-PC clinical trial. The trial aims to evaluate the effectiveness of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in combination with mFOLFIRINOX compared to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer. Previous data has shown that OT-101 has significant activity as a standalone treatment, with reported overall survival rates surpassing existing drug outcomes. In this phase 2/3 trial, participants will be assigned to either receive OT-101 plus mFOLFIRINOX or mFOLFIRINOX alone as second-line therapy after their cancer has progressed. "STOP-PC trial is the combination of mFOLFIRINOX and OT-101 based on our demonstration that reduced TGF- β2 resulted in outstanding improvement in survival among patients treated with Irinotecan with survival beyond 34 months for the low TGF-β2 expression cohort. The mFOLFIRINOX was chosen as the most well tolerated combination of choice through discussion with regulatory authorities and key opinion leaders. We believe this trial will deliver the decisive win against pancreatic cancer," said Dr. Vuong Trieu, CEO of Oncotelic. To learn more about participation in STOP-PC Clinical Trial click here or watch this explainer video here. Featured photo by Alexander Grey on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 Company Website

April 10, 2024 08:30 AM Eastern Daylight Time

Article thumbnail News Release

Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices

Vivos Therapeutics

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive shared significant news regarding the regulatory approval for Medicare reimbursement of their oral medical devices designed for sleep apnea treatment. Huntsman emphasized the unique design of Vivos's medical devices, which are capable of enhancing the human airway and potentially eliminating sleep apnea symptoms after a 12-month treatment period. This FDA clearance positions Vivos as the only line of oral medical devices globally that can treat severe sleep apnea. The approval for Medicare reimbursement is described as a monumental achievement, as it is expected to benefit tens of millions of Medicare patients suffering from moderate to severe obstructive sleep apnea (OSA) without the need for lifetime intervention. This recognition by the Centers for Medicare and Medicaid Services (CMS) propels Vivos's devices as a viable alternative to traditional CPAP treatments, especially timely given the recent recalls in the CPAP market and Philips' withdrawal from the U.S. market. Huntsman expressed his excitement about the broader implications of this approval, including increased recommendations of Vivos's treatments by medical and dental providers and a growing awareness of their efficacy as an alternative to CPAP treatments. This development represents a significant step forward in transforming patient care for individuals suffering from sleep apnea. Watch the full interview to learn more about Vivos Therapeutics Inc.'s pioneering approach to treating sleep apnea and their vision for improving patient care. Contact Details Proactive Investors +1 347-449-0879

April 09, 2024 11:45 AM Pacific Daylight Time

Article thumbnail News Release

FITPAL LLC Announces a Holistic Approach to Health Management: Combining GLP-1 Treatments, DEXA Scans, and Digital Health Tools

Rev Up Marketers

FITPAL LLC is proud to announce a comprehensive approach to health management that combines GLP-1 treatments, DEXA scans, and its innovative Fitpal Pro App. This program goes beyond traditional methods by focusing on a multifaceted approach to wellness, equipping individuals with the tools and knowledge they need to achieve their health goals. GLP-1 Treatments: A Promising Avenue for Metabolic Health Glucagon-like peptide-1 (GLP-1) treatments have emerged as a significant advancement in managing metabolic health. GLP-1 receptors are naturally found in the gut and pancreas, and GLP-1 drugs mimic the effects of the GLP-1 hormone. These treatments have been shown to improve glycemic control, increase satiety, and potentially offer other cardiovascular benefits. When incorporated into a personalized healthcare plan, these treatments can be a valuable tool for individuals seeking to manage blood sugar levels and support overall metabolic health. However, it is crucial to consult with a healthcare professional to determine if GLP-1 treatment is suitable for each specific case. DEXA Scans: Providing Insights into Body Composition DEXA scans, also known as dual-energy X-ray absorptiometry scans, are a type of bone density scan that offers valuable insights into body composition. They measure bone mineral density (BMD), which is a crucial indicator of bone health. Additionally, they can differentiate between bone mass, muscle mass, and body fat percentage. By providing a detailed dexa body composition analysis, these scans can be instrumental in guiding treatment plans and monitoring progress. For instance, they can help assess the effectiveness of weight management programs or track changes in muscle mass over time. Fitpal Pro App: A Digital Health Tool to Empower Individuals The Fitpal Pro App serves as the cornerstone of this comprehensive health management program. This App provides users with personalized meal plans, calorie tracking tools, and fitness routines tailored to their individual needs and goals. The app also integrates with wearable devices to monitor activity levels and sleep patterns, providing valuable insights into overall health and well-being. A Symbiotic Relationship: Combining Technologies for Optimal Health The unique combination of GLP-1 treatments, DEXA scans, and the Fitpal Pro App fosters a symbiotic relationship that empowers individuals to take a proactive approach to their health. GLP-1 treatments can support metabolic health, while DEXA scans provide valuable insights into body composition. The Fitpal Pro App serves as a central hub, allowing users to track progress, access educational resources, and stay connected with their healthcare providers. This initiative by FITPAL LLC signifies a shift towards a more holistic approach to health management, focusing on personalized care and providing individuals with the knowledge and resources they need to thrive. For any press-related queries or additional details, please mail to or visit Groupon: Contact Details Fitpal LLC Media Relations +1 646-437-8646 Company Website

April 09, 2024 02:07 PM Eastern Daylight Time

Article thumbnail News Release

From AI To Foodtech, OurCrowd Brings More Opportunities To Investors With Three New Funds


By Meg Flippin, Benzinga When it comes to transformative, revolutionary technology, AI is high on the list. After all, it impacts everything from how we craft research papers and emails to what we eat. It is also driving unprecedented deal-making with investment dollars pouring into AI and generative AI at a fast clip, with those investments also naturally spilling over into other impacted sectors like foodtech. OurCrowd, the leading global digital investment firm, captures all of those opportunities and more with three popular investment funds: The OurCrowd AI Fund, The OurCrowd FoodTech Fund and OC50 VIII. Through these funds, investors get access to the startups OurCrowd is making bets on in fast-growing markets like AI, foodtech and software-as-a-service, to name a few. Declared Israel’s “most active investor” for the past 10 years by PitchBook, OurCrowd has recorded 63 exits from 440 portfolio companies since its inception in 2013 and is invested in 410 additional companies via partner funds. It has more than 230,000 registered investors from 195 countries among its members. Through the OurCrowd platform, accredited investors can participate in a wide range of deals from individual startups to highly diversified funds, private equity, venture debt and other hard-to-access private market opportunities. OurCrowd gives investors access to multiple funds based on sector, stage, geography or investment thesis. Generative AI Transforming The World The OurCrowd AI Fund is one example of the types of opportunities OurCrowd offers. The $50 million fund seeks appreciation by investing in 20 to 25 AI startups on the OurCrowd platform using AI, generative AI and machine learning to positively impact multiple industries and sectors. The fund is focused on companies developing generative AI across several sectors, including medtech, mobility, agtech, cybersecurity, foodtech, climatech, legaltech and fintech. The fund will also invest in companies that provide AI solutions to support key business categories across technology sectors, including customer operations, marketing and sales, software engineering and R&D. OurCrowd sees a big opportunity for the startups operating in the generative AI space, pointing to ChatGPT to underscore the potential. “Since the release of OpenAI’s ChatGPT in November 2022 the interest in artificial intelligence (AI) and particularly in generative AI has surged. The remarkable success of ChatGPT is a testament to the power of product/market fit,” OurCrowd wrote in its investment prospectus for the fund. “Launched on November 30, 2022, it gained over 1 million users in just 5 days and reached 100M users in just 2 months. This level of mass adoption for a technology product is unprecedented, way outpacing previous tech innovative waves such as the PC (it took Apple 14 years and Microsoft 10 years to attain 100M users), Internet (Amazon – 12 years, Facebook 5 years and Google raised the bar to 1 year), Mobile (Instagram – 30 months and TikTok – 9 months).” To learn more about the OurCrowd AI Fund and to invest, click here. Technology Changing The Way We Eat Foodtech is another area OurCrowd is bullish about and so it has launched the OurCrowd FoodTech Fund. The fund is raising $30 million to invest in 15 to 20 food technology companies offered on the OurCrowd platform. OurCrowd says the foodtech market is booming, with a few areas of the market dominating, including bioengineering alternative proteins, supply-chain optimization, AI-driven smart home cooking products and delivery apps. The OurCrowd FoodTech Fund invests in a wide range of technology companies seeking to tackle the challenge of feeding the world’s fast-growing population while decarbonizing the global economy. Companies in the fund will also address new trends in culinary preferences, as well as lifestyle pressures and sustainability demands among Millennials and Generation Z. OurCrowd knows a thing or two about foodtech, which is what it says makes its fund attractive to accredited investors. The VC firm has invested more than $102 million across 20 foodtech companies worldwide, including Beyond Meat Inc. (NASDAQ: BYND), which had a successful IPO in 2019. Of its investments, nine are in Israel, which is a global leader in the number of alternative protein startups and amount invested, second only to the U.S. OurCrowd says it’s well positioned to leverage Israel’s cutting-edge leadership in the space via its network of entrepreneurs, scientists, third-party funds and dedicated in-house food and agtech incubators in Israel and New Zealand. Moreover, since 2021, OurCrowd has been among the ten most active VCs globally in foodtech, according to PitchBook data. To learn more about the OC FoodTech fund and how to invest click here. VC Access Through OurCrowd’s OC50 VIII Fund With so many startups in AI, foodtech and other areas of technology, it's not surprising that a lot of deal-making is going on. OurCrowd is giving investors access to that via its hyperdiversified OC50 VIII fund. Through the fund, investors get unprecedented broad exposure to the venture capital asset class across technology sectors where OurCrowd professionals have developed particular expertise, geographies where OurCrowd has developed networks of investors and global partners and across all development stages of startup companies from early-stage to pre-IPO. The investments cover several areas of tech including software-as-a-service (SaaS), fintech, medtech and digital health, mobility, cybersecurity and consumer and enterprise hardware. OurCrowd is leveling the playing field with the fund, giving investors access to venture deals long reserved only for institutional investors and elite VCs – offering instant diversification, rapid deployment of funds, earlier distributions and preferential access to the OurCrowd platform’s top deals. To invest in the OC50 VIII fund and learn more about its strategy click here. Beyond AI And Tech OurCrowd isn’t only focusing on AI and food tech, it's also adapting to geopolitical unrest, recently launching the $50 million Israel Resilience Fund. The fund is focused on startups that are directly affected by the Israeli/Hamas conflict or are developing solutions to address the environmental impact, emergency medicine, food security, cybersecurity, media monitoring, reconstruction and other verticals. That fund closed its first round 40 days after announcing, with $13 million in capital commitments. It's one of the fastest-closing venture funds to go from conception to closure and eight actual investments, according to OurCrowd. The fund plans to invest in about 40 companies and has so far helped to unlock more than $100 million in matching funds from other investors and government bodies. For an opportunity to get in early on the Israeli companies making a difference despite the Israeli/Hamas conflict click here. Change is happening at a dizzying pace driven by AI, generative AI and machine learning. Through these funds from OurCrowd, investors get early access to up-and-coming startups that have the potential to be the leaders of tomorrow. Click here to begin investing with OurCrowd. Featured photo by Steve Johnson on Unsplash. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Lisa Graston Company Website

April 09, 2024 08:45 AM Eastern Daylight Time

Article thumbnail News Release

hVIVO achieves record revenue and initiates dividend policy following successful year


hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin increase from 18.7% to 23.3%, surpassing prior guidance. The company's absolute EBITDA rose to £30 million, a 44% increase from the previous year. Khan attributed the success to hVIVO conducting more human challenge trials, leading to improved patient recruitment efficiency and better utilisation of facilities and staff. Despite challenges such as MHRA delays, significant funding for a new Canary Wharf facility positively impacted the financial results. hVIVO also initiated an annual dividend policy, planning a £1.4 million dividend distribution following a strong cash generation year. The Canary Wharf facility's development, notably ahead of schedule, includes a 50-bed quarantine facility and a laboratory, set to be fully operational by the end of July. This expansion is expected to enhance operational efficiency, increase revenue potential to up to £95 million, and strengthen hVIVO's position in the human challenge trial industry globally. For 2024, the company anticipates hitting a £62 million revenue target, with £180 million in the weighted order book ensuring a robust pipeline. Despite a study cancellation, hVIVO remains confident in its revenue and EBIT margin targets. Looking forward, hVIVO aims for a £100 million revenue target by 2028, driven by expanding its human challenge trials, increasing clinical trial services, and exploring M&A activities, supported by a strong cash reserve. Contact Details Proactive UK Ltd +44 20 7989 0813

April 09, 2024 07:51 AM Eastern Daylight Time

Article thumbnail News Release

Genflow Biosciences attracts new institutional investors with £715,000 fundraise

Genflow Biosciences PLC

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire tells Proactive's Stephen Gunnion the company has successfully raised £715,000 through a mix of placements and subscriptions for new stock. This fundraising effort was notably supported by company directors, including Leire, and new institutional investors. Leire highlighted the importance of this move as a strategic effort to stabilise and grow the company, especially noting the significance of attracting institutional investment. Historically, Genflow relied on grants and research funding, making this step a notable shift in its funding strategy. Leire also mentioned the company's focus on longevity and healthspan, pointing out the increasing gap between lifespan and healthspan as a major healthcare and economic challenge. Genflow's approach to addressing age-related diseases has started to attract attention from the institutional market, recognizing the potential high upside in the longevity sector. The funds raised are earmarked for continuing clinical trials in their three main programs: progeria, non-alcoholic steatohepatitis (NASH), and sarcopenia, aiming to reduce both financial and scientific risks by diversifying their portfolio. Contact Details Proactive UK Ltd +44 20 7989 0813

April 08, 2024 11:13 AM Eastern Daylight Time

12345 ... 268